Search

News type
1810 - 1818 of 2152 results
Search result from the Trials Tracker

CF Tummy Tracker

Study details

Tummy symptoms such as bloating, pain and nausea are common for people with cystic fibrosis (CF). These symptoms can be embarrassing and disruptive to everyday life. Despite this, most questionnaires used in CF research are not actually CF-specific. We need to change this. It is important that we have a CF-specific tool so that researchers can understand the daily impact of tummy symptoms for people with CF when it comes to studies, trials, treatments and ongoing care. This will help us address the CF tummy issues that matter most to YOU. Not just the things that clinicians and researchers think...

Study results summary

151 people with CF signed up to test CF Tummy Tracker® in a smartphone app. Nearly all said the questions were clear, relevant and helped them become more aware of their tummy symptoms. Participants said the app was quick to use, simple to navigate, and almost 7 out of 10 said they would use the app again. The full results are available on the CF Tummy Tracker website.

Click below to find out more. Find out more
Trials Tracker ID
TT009111
Age range
Aged 12 years and older
Length of participation
14 days (2 weeks)
Trial status
Recruitment complete
Therapeutic approach
Nutritional-GI
Remote participation
Remote participation is possible for this trial
Search result from the Trials Tracker

Lenticlair (TM) 1: A study to assess how well a new genetic therapy is tolerated and whether it improves lung function in people with CF

CTAP badge
Study details

Boehringer Ingelheim has made the decision to stop the investigation of the potential cystic fibrosis gene therapy (BI 3720931) and therefore terminated the Lenticlair TM 1 trial (1504-0001). This decision is based on clinical data that - in the opinion of Boehringer Ingelheim - does not support continuing this trial and does not relate to any changes in the safety profile of the treatment. This study, called Lenticlair TM 1, aims to find out how well a new genetic therapy is tolerated and whether it improves lung function in people with CF. This is the first time that the genetic...

Click below to find out more. Find out more
Trials Tracker ID
TT014335
Age range
18 years and older
Length of participation
28 Weeks
Trial status
Study discontinued early
Therapeutic approach
Genetic Therapy

Developing effective treatment options for everyone with cystic fibrosis

Blog - Published Date:

One of our research goals is to develop effective treatment options for all. To mark Rare Disease Day we recap on some of the research studies that are underway which focus on the development of new treatments for those who have been unable to benefit from current modulators.

Acknowledging our support

Please acknowledge Cystic Fibrosis Trust support in research papers, conference abstracts and in posters and talks. This applies if you’ve received research funding from us or data from UK CF Registry.

Alyftrek available in Scotland

News - Published Date:

Today (9 March) the Scottish Medicines Consortium (SMC) Committee have accepted Alyftrek for use in Scotland. This follows approval in England, Northern Ireland and Wales.